Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Aims To Grow Seroquel XR With Added Indications, Not Switches

Executive Summary

AstraZeneca is looking to establish Seroquel XR, the sustained-release line extension of its atypical antipsychotic quetiapine, by adding unique indications rather than pushing to switch patients from immediate-release Seroquel

You may also be interested in...



Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent

FDA's decision to review its approval of a generic for Valeant's topical Efudex (fluorouracil) Cream 5% may create a precedent for future approvals of ANDAs for complex small molecule drugs and could set the stage for higher hurdles for eventual approvals of biogenerics

Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent

FDA's decision to review its approval of a generic for Valeant's topical Efudex (fluorouracil) Cream 5% may create a precedent for future approvals of ANDAs for complex small molecule drugs and could set the stage for higher hurdles for eventual approvals of biogenerics

AstraZeneca Sales Force Restructuring Boosts Operating Profit, Not Sales

AstraZeneca's efforts to restructure its EU sales force have helped the company improve its margins

Related Content

UsernamePublicRestriction

Register

PS048956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel